Markets
TMO

Henry Schein (HSIC) Inks Distribution Agreement with Terason

Henry Schein Medical, a subsidiary of Henry Schein, Inc.HSIC , announced an exclusive distribution agreement with Terason to distribute the latter's uSmart 3200T NexGen. This development remains a part of Henry Schein Medical's Emergency Medical Services ("EMS") business.

Terason a division of Teratech Corporation is a manufacturer of portable ultrasound machine. uSmart 3200T is a portable ultrasound device that allows emergency responders to carry out exams in emergency medical transport vehicles and aircrafts. This reduces the need to speculate for EMS professionals. uSmart 3200T NexGen is a portable light-weight ultrasound tablet, easy to transport and operate.

The Terason uSmart 3200T features many advanced features including customized presets, fast boot-up, grab-and-go portability and Wi-Fi capabilities. Responders can recognize issues at the point-of-care, during transportation and also alert emergency room staff of important vitals with uSmart 3200T. According to the company, accessing patient's vitals will help emergency responders make more informed decisions on treatment. Also, it helps emergency room staff to prepare ahead of the patient's arrival.

Henry Schein is consistently working toward boosting its Medical segment. Notably, worldwide Medical revenues rose 6.1% year over year in the last reported second quarter. Henry Schein Medical recently inked an agreement with Cerebral Assessment Systems ("CAS") to distribute Cognivue. This is the first computerized cognitive assessment screening device cleared by the FDA for the detection of early signs of dementia. Moreover, Henry Schein announced a partnership with Simplifeye to create a mobile platform for health care providers who use its practice management and electronic health record software - MicroMD.

According to a report by Markets and Markets, the ultrasound market is expected to reach a value of $6.86 billion by 2021, at a CAGR of 5.2% during 2016 to 2021. Considering the substantial potential of the market, we believe the latest development is a strategic one.

Over the past year, Henry Schein has underperformed the broader industry . The stock has gained 6.8%, compared with the 10.3% gain of the broader industry.

Estimate Revision Trend

The estimate revision trend has been favorable for the company. For the current quarter, two estimates moved north compared with five movements in the opposite direction over the last two months. As a result, the Zacks Consensus Estimate for current-quarter earnings per share has increased to 90 cents from 89 cents.

Zacks Rank & Key Picks

Henry Schein has a Zacks Rank #3 (Hold). A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Abbott, IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Abbott has a long-term expected earnings growth rate of 10.7%. The stock rallied roughly 32.7% over the last year.

IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock gained 40.9% last year.

Thermo Fisher has a long-term expected earnings growth rate of 11.7%. The stock gained 26.1% last year.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Abbott Laboratories (ABT): Free Stock Analysis Report

Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report

IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report

Henry Schein, Inc. (HSIC): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

TMO HSIC IDXX ABT

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More